Insider · CIK 0001691160
Edward J. Benz JR
Files at DCPH (Deciphera Pharmaceuticals, Inc.), RCOR (Renovacor, Inc.), CADL (Candel Therapeutics, Inc.). First filing -, latest -.
In brief
Edward J. Benz JR files SEC Form 4 as director at DCPH (Deciphera Pharmaceuticals, Inc.), and also at RCOR (Renovacor, Inc.), CADL (Candel Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Edward J. Benz JR has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 16 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 23, 2026 | CADL Candel Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +32,000 | $0.00 | $0 | 32,000 | Jun 24, 2026 |
| Jun 17, 2025 | CADL Candel Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +14,240 | $0.00 | $0 | 14,240 | Jun 18, 2025 |
| Jun 26, 2024 | CADL Candel Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +14,240 | $0.00 | $0 | 14,240 | Jun 27, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -35,233 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,181 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,000 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -18,500 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -30,000 | - | - | 0 | Jun 11, 2024 |
| Jun 28, 2023 | CADL Candel Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +14,240 | $0.00 | $0 | 14,240 | Jun 29, 2023 |
| Jun 21, 2023 | DCPH Deciphera Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 23, 2023 |
| Dec 1, 2022 | RCOR Renovacor, Inc. | AGrant or award Common Stock | +3,586 | - | - | 3,586 | Dec 5, 2022 |
| Dec 1, 2022 | RCOR Renovacor, Inc. | DDisposition to issuer Common Stock | -3,586 | - | - | 0 | Dec 5, 2022 |
| Dec 1, 2022 | RCOR Renovacor, Inc. | DDisposition to issuer Stock Optionderivative | -9,060 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | RCOR Renovacor, Inc. | DDisposition to issuer Stock Optionderivative | -24,000 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Dec 1, 2022 | RCOR Renovacor, Inc. | DDisposition to issuer Stock Optionderivative | -12,000 | $0.00 | $0 | 0 | Dec 5, 2022 |
| Oct 13, 2022 | CADL Candel Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +14,240 | $0.00 | $0 | 14,240 | Oct 17, 2022 |
Questions about Edward J. Benz JR
Answered from the filings on this page, as of the latest one.
Is Edward J. Benz JR buying or selling?
Edward J. Benz JR has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Edward J. Benz JR's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Edward J. Benz JR has 0.
Where does Edward J. Benz JR file Form 4?
Edward J. Benz JR has filed Form 4 at DCPH (Deciphera Pharmaceuticals, Inc.); RCOR (Renovacor, Inc.); CADL (Candel Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.